Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Free Cash Flow: 2015-2024

Historic Free Cash Flow for UroGen Pharma (URGN) over the last 10 years, with Dec 2024 value amounting to -$97.1 million.

  • UroGen Pharma's Free Cash Flow fell 52.58% to -$42.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$138.1 million, marking a year-over-year decrease of 43.31%. This contributed to the annual value of -$97.1 million for FY2024, which is 26.76% down from last year.
  • According to the latest figures from FY2024, UroGen Pharma's Free Cash Flow is -$97.1 million, which was down 26.76% from -$76.6 million recorded in FY2023.
  • UroGen Pharma's Free Cash Flow's 5-year high stood at -$76.6 million during FY2023, with a 5-year trough of -$107.1 million in FY2020.
  • Its 3-year average for Free Cash Flow is -$87.1 million, with a median of -$87.8 million in 2022.
  • Per our database at Business Quant, UroGen Pharma's Free Cash Flow slumped by 50.12% in 2020 and then rose by 20.03% in 2021.
  • Over the past 5 years, UroGen Pharma's Free Cash Flow (Yearly) stood at -$107.1 million in 2020, then increased by 20.03% to -$85.6 million in 2021, then fell by 2.53% to -$87.8 million in 2022, then increased by 12.80% to -$76.6 million in 2023, then dropped by 26.76% to -$97.1 million in 2024.